Press Release

Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.

Insider information pursuant to Article 17 MAR


Q3 2023:

  • sales of 65.9 million EUR (previous year: 57.2 million EUR)
  • profit of 9.4 million EUR (previous year: 7.9 million EUR)

First 9 months of 2023:

  • sales of 183.9 million EUR (previous year: 164.0 million EUR)
  • profit of 20.3 million EUR (previous year: 23.3 million EUR)

Forecast 2023:

  • sales of just under 230 million EUR (confirmed)
  • profit of around EUR 25 million (confirmed)

Berlin, October 17, 2023. According to preliminary calculations, Eckert & Ziegler AG (ISIN DE0005659700, SDAX) achieves sales of 183.9 million EUR (previous year: 164.0) and a profit of around 20.3 million EUR (previous year: 23.3) for the first nine months of 2023.

Sales increased by around 12% compared to the same period of the previous year. The main driver of this development is the continuing demand for radioisotopes for pharmaceutical applications, which led to growth of around 27% in the Medical segment.

In addition to increased expenditure for capacity expansions, the main drivers of the decline in earnings compared to the previous year are currency effects as well as inflation adjustments in the hyperinflationary country of Argentina, which were not included in the first nine months of the previous year; these amount to around 4.5 million EUR.

The forecast for fiscal year 2023 published on March 30, 2023 with sales of just under EUR 230 million and net income of around EUR 25 million remains unchanged.

The complete figures for the first nine months of 2023 will be published on November 14, 2023.

Contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com 



End of Inside Information

17-Oct-2023 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler Strahlen- und Medizintechnik AG
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-112
E-mail: karolin.riehle@ezag.de
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1750997

<br/>

 
End of Announcement EQS News Service

show this